MSD’s sotatercept has become the first FDA-approved therapy for pulmonary arterial hypertension (PAH) that addresses the underlying mechanism behind the disease, rather than its symptoms.

Dr Mendiratta further informed that innovative emerging therapies include recombinant fusion protein like Sotatercept. It modifies growth signals to prevent abnormal blood vessel growth, a promising ...

At the American College of Cardiology (ACC) meeting this week, Merck showcased two components of its cardiovascular pipeline – sotatercept for pulmonary arterial hypertension (PAH) and oral ...

which also goes by the name sotatercept, was originally picked up via Merck’s $11.5 billion acquisition of Acceleron back in 2021. The U.K.’s Medicines and Healthcare products Regulatory ...